Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study

International Journal of Antimicrobial Agents

Volumn 36, Issue 3, 2010, Pages 293-294

  Hawser, Stephen P ^a   Badal, Robert E ^b   Bouchillon, Samuel K ^b   Hoban, Daryl J ^b   Hsueh, Po Ren ^c  

^a International Health Management Associates Europe Sàrl   (Switzerland)

^b International Health Management Associates   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; ESCHERICHIA COLI; INFECTION CONTROL; INTERMETHOD COMPARISON; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; COMPARATIVE STUDY; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; EVALUATION STUDY; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 77954954787     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.05.012     Document Type: Letter

References (7)

1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
2. Tumbarello M., Sanguinetti M., Montuori E., Trecarichi E.M., Posteraro B., Fiori B., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51:1987-1994.
3. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E., Hsueh P.R., Paterson D.L. Emergence of high levels of extended-spectrum-β-lactamase-producing Gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009, 53:3280-3284.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
5. European Committee on Antimicrobial Susceptibility Testing (EUCAST) [accessed 26 May 2010]. http://www.eucast.org/.
6. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M07-A7. Wayne, PA: CLSI; 2008.
7. Bhavnani S., Ambrose P.G., Craig W.A., Dudley M.N., Jones R.N. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006, 54:231-236. SENTRY Antimicrobial Surveillance Program.